In the latest trading session, 1.37 million Unicycive Therapeutics Inc (NASDAQ:UNCY) shares changed hands as the company’s beta touched 2.32. With the company’s most recent per share price at $0.68 changing hands around $0.02 or 2.05% at last look, the market valuation stands at $70.37M. UNCY’s current price is a discount, trading about -167.65% off its 52-week high of $1.82. The share price had its 52-week low at $0.20, which suggests the last value was 70.59% up since then. When we look at Unicycive Therapeutics Inc’s average trading volume, we note the 10-day average is 1.47 million shares, with the 3-month average coming to 1.58 million.
Analysts gave the Unicycive Therapeutics Inc (UNCY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended UNCY as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Unicycive Therapeutics Inc’s EPS for the current quarter is expected to be -0.07.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Instantly UNCY is in green as seen in intraday trades today. With action -12.98%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -14.63%, with the 5-day performance at -12.98% in the red. However, in the 30-day time frame, Unicycive Therapeutics Inc (NASDAQ:UNCY) is -15.04% down. Looking at the short shares, we see there were 1.05 million shares sold at short interest cover period of 0.74 days.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Data shows that the Unicycive Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 37.00% over the past 6 months, a 5.00% in annual growth rate that is considerably lower than the industry average of 16.20%. Year-over-year growth is forecast to reach -100.00% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -77.09%. The 2025 estimates are for Unicycive Therapeutics Inc earnings to increase by 59.82%.
UNCY Dividends
Unicycive Therapeutics Inc is expected to release its next quarterly earnings report in February.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.73% of Unicycive Therapeutics Inc shares while 38.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 41.00%. There are 38.24% institutions holding the Unicycive Therapeutics Inc stock share, with VIVO CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 9.9395% of the shares, roughly 3.47 million UNCY shares worth $1.74 million.
LOGOS GLOBAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.9389% or 3.47 million shares worth $1.74 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 765.0 shares estimated at $0.51 million under it, the former controlled 0.74% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.36% of the shares, roughly 373.22 shares worth around $0.25 million.
